Mycophenolate mofetil: emerging as a potential human teratogen.
ABSTRACTQUESTION One of my female patients conceived 2 years after renal transplant while using mycophenolate mofetil. She only realized she was pregnant at 14 weeks of gestation. How should I advise her?ANSWER Several recent case series show increased malformation rates with mycophenolate mofetil. Specifically, the repeated occurrence of phenotypic presentations of ear malformations, cleft lip and palate, and other malformations suggest that this is not by chance alone.
Koren
Gideon
G
D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016377:Organ Transplantation; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011270:Pregnancy, Animal; D018566:Pregnancy, High-Risk; D011295:Prenatal Care / Q000379:methods; D011817:Rabbits; D051381:Rats; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013723:Teratogens / Q000494:pharmacology*; D014181:Transplantation Immunology
D007166:Immunosuppressive Agents; D013723:Teratogens; D009173:Mycophenolic Acid